Search research articles
Contact Us
Filters
Showing results (61-70 of 76) with videos related to
Page
of 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial
T Powles, S A Hussain, M A Climent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 11, 2025
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
T Powles, S Tagawa, C Vulsteke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 23, 2022
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients
J Chen, F Facchinetti, F Braye, et al.
BMC Cancer
|
May 25, 2021
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
P Grivas, Y Loriot, R Morales-Barrera, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 5, 2011
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
M Bachner, Y Loriot, M Gross-Goupil, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 18, 2017
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases
Y Loriot, L Pagliaro, A Fléchon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 3, 2025
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial
T B Powles, M S Van der Heijden, Y Loriot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 1, 2025
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial
B Tombal, A Choudhury, F Saad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2026
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer
S Gillessen, E Gallardo, A Choudhury, et al.
ESMO Open
|
December 6, 2024
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial
J E Rosenberg, M D Galsky, T Powles, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 76) with videos related to
Sort By:
Page
of 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial
T Powles, S A Hussain, M A Climent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 11, 2025
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
T Powles, S Tagawa, C Vulsteke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 23, 2022
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients
J Chen, F Facchinetti, F Braye, et al.
BMC Cancer
|
May 25, 2021
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
P Grivas, Y Loriot, R Morales-Barrera, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 5, 2011
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
M Bachner, Y Loriot, M Gross-Goupil, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 18, 2017
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases
Y Loriot, L Pagliaro, A Fléchon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 3, 2025
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial
T B Powles, M S Van der Heijden, Y Loriot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 1, 2025
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial
B Tombal, A Choudhury, F Saad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2026
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer
S Gillessen, E Gallardo, A Choudhury, et al.
ESMO Open
|
December 6, 2024
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial
J E Rosenberg, M D Galsky, T Powles, et al.
Page
of 8